Impact of the First Wave of the COVID-19 Pandemic on the Lyon University Hospital Cancer Institute (IC-HCL).
Anne-Sophie BelmontChristophe SajousAmandine BruyasSara CalattiniStéphanie CartalatMarion ChauvenetMarc ColombelStéphane DalleTristan DagonneauMarie DarrasonGilles DevouassouxMichaël DuruisseauxMarielle GuilletOlivier GlehenPierre PhilouzeFrançois TroncThomas WalterBenoît YouGilles FreyerPublished in: Cancers (2021)
This article presents the protective measures put in place at the "Institut de Cancérologie des Hospices de Lyon" (IC-HCL) during the first wave of the COVID-19 pandemic in France (spring 2020) and how they impacted IC-HCL clinical activity. Spring 2020 activities were compared to winter 2019-2020. Results showed a decrease of activity of 9% for treatment dispensations, 17% for multidisciplinary team meetings, 20% for head and neck and thoracic surgeries, and 58% for new patient enrolment in clinical trials. Characteristics of patients treated for solid cancer and hospitalized for COVID-19 during spring 2020 were collected in a retrospective study. Mortality was attributed to COVID-19 for half of the cases, 82% being patients above 70 and 73% being stage IV. This is in concordance with current findings concluding that the risk of developing severe or critical symptoms of COVID-19 is correlated with factors co-occurring in cancer patients and not to the cancer condition per se. While a number of routines and treatment regimens were changed, there was no major decline in numbers of treatments conducted at the IC-HCL during the first wave of the COVID-19 pandemic that hit France between March and May 2020, except for clinical trials and some surgery activities.
Keyphrases
- coronavirus disease
- clinical trial
- papillary thyroid
- sars cov
- squamous cell
- minimally invasive
- newly diagnosed
- palliative care
- type diabetes
- quality improvement
- childhood cancer
- risk factors
- ejection fraction
- cardiovascular events
- case report
- acute coronary syndrome
- physical activity
- health insurance
- cardiovascular disease
- respiratory syndrome coronavirus
- early onset
- patient reported outcomes
- coronary artery disease
- phase ii
- depressive symptoms
- coronary artery bypass
- spinal cord injury
- sleep quality